Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on LivaNova PLC (LIVN) and Sarepta Therapeutics (SRPT).
LivaNova PLC (LIVN)
Needham analyst Michael Matson reiterated a Buy rating on LivaNova PLC today and set a price target of $120. The company’s shares opened today at $96.25.
Matson wrote:
“LIVN beat consensus revenue and EPS in 4Q18. Management provided 2019 revenue growth guidance that was above consensus at the mid-point and adjusted EPS guidance that was below consensus due to treatment- resistant depression (TRD) investments (costing $0.15-0.20 of EPS). Organic revenue growth slowed to 7% in 4Q18 from 8% in 3Q18 given a tougher comp and weakness in Cardiovascular, slightly offset by strength in Neuromodulation. Gross margin was up 470 bps Y/Y while operating margin was up 80 bps Y/Y due to SG&A and R&D investments to fund current and future growth initiatives. While we expect LIVN’s reinvestment to weigh on its margins and EPS in the near-term, we believe it will drive faster revenue growth in future periods and we reiterate our Buy rating.”
According to TipRanks.com, Matson is a top 100 analyst with an average return of 13.9% and a 69.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
LivaNova PLC has an analyst consensus of Strong Buy, with a price target consensus of $134.75, which is a 40.0% upside from current levels. In a report issued on February 15, Berenberg Bank also maintained a Buy rating on the stock with a $135 price target.
See today’s analyst top recommended stocks >>
Sarepta Therapeutics (SRPT)
Oppenheimer analyst Hartaj Singh assigned a Hold rating to Sarepta Therapeutics today. The company’s shares opened today at $151.99.
According to TipRanks.com, Singh is a 3-star analyst with an average return of 1.5% and a 44.7% success rate. Singh covers the Healthcare sector, focusing on stocks such as Strongbridge Biopharma Plc, Catabasis Pharmaceuticals, and Actinium Pharmaceuticals.
Currently, the analyst consensus on Sarepta Therapeutics is a Strong Buy with an average price target of $202.62.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRPT:
